| Treatment of HCV infection by targeting microRNA HLA Janssen, HW Reesink, EJ Lawitz, S Zeuzem, M Rodriguez-Torres, ... New England Journal of Medicine 368 (18), 1685-1694, 2013 | 2533 | 2013 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1422 | 2013 |
| Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C JG McHutchison, M Manns, K Patel, T Poynard, KL Lindsay, C Trepo, ... Gastroenterology 123 (4), 1061-1069, 2002 | 1328 | 2002 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1051 | 2019 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1044 | 2015 |
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus AJ Thompson, AJ Muir, MS Sulkowski, D Ge, J Fellay, KV Shianna, ... Gastroenterology 139 (1), 120-129. e18, 2010 | 959 | 2010 |
| Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients K Patel, SC Gordon, I Jacobson, C Hézode, E Oh, KM Smith, ... Journal of hepatology 41 (6), 935-942, 2004 | 492 | 2004 |
| The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients HM Patton, K Patel, C Behling, D Bylund, LM Blatt, M Vallée, S Heaton, ... Journal of hepatology 40 (3), 484-490, 2004 | 472 | 2004 |
| IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C TJ Urban, AJ Thompson, SS Bradrick, J Fellay, D Schuppan, KD Cronin, ... Hepatology 52 (6), 1888-1896, 2010 | 463 | 2010 |
| Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin JJ McCarthy, JH Li, A Thompson, S Suchindran, XQ Lao, K Patel, ... Gastroenterology 138 (7), 2307-2314, 2010 | 456 | 2010 |
| A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice HL Tillmann, AJ Thompson, K Patel, M Wiese, H Tenckhoff, HD Nischalke, ... Gastroenterology 139 (5), 1586-1592. e1, 2010 | 425 | 2010 |
| An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response A Mangia, AJ Thompson, R Santoro, V Piazzolla, HL Tillmann, K Patel, ... Gastroenterology 139 (3), 821-827. e1, 2010 | 420 | 2010 |
| Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication M Bouvier‐Alias, K Patel, H Dahari, S Beaucourt, P Larderie, L Blatt, ... Hepatology 36 (1), 211-218, 2002 | 306 | 2002 |
| Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study NH Afdhal, BR Bacon, K Patel, EJ Lawitz, SC Gordon, DR Nelson, ... Clinical gastroenterology and hepatology 13 (4), 772-779. e3, 2015 | 242 | 2015 |
| Hepatitis B virus–specific and global T-cell dysfunction in chronic hepatitis B JJ Park, DK Wong, AS Wahed, WM Lee, JJ Feld, N Terrault, M Khalili, ... Gastroenterology 150 (3), 684-695. e5, 2016 | 240 | 2016 |
| Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial K Patel, SA Harrison, M Elkhashab, JF Trotter, R Herring, SE Rojter, ... Hepatology 72 (1), 58-71, 2020 | 233 | 2020 |
| Risks of a range of alcohol intake on hepatitis C‐related fibrosis A Monto, K Patel, A Bostrom, S Pianko, P Pockros, JG McHutchison, ... Hepatology 39 (3), 826-834, 2004 | 230 | 2004 |
| Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction AJ Thompson, J Fellay, K Patel, HL Tillmann, S Naggie, D Ge, TJ Urban, ... Gastroenterology 139 (4), 1181-1189. e2, 2010 | 226 | 2010 |
| Limitations of non-invasive tests for assessment of liver fibrosis K Patel, G Sebastiani JHEP Reports 2 (2), 100067, 2020 | 205 | 2020 |
| Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH R Loomba, M Noureddin, KV Kowdley, A Kohli, A Sheikh, G Neff, ... Hepatology 73 (2), 625-643, 2021 | 184 | 2021 |
